Home22UA • ETR
add
BioNTech
Nakaraang pagsara
€75.90
Sakop ng araw
€76.50 - €78.00
Sakop ng taon
€68.30 - €110.90
Market cap
23.55B USD
Average na Volume
91.20K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (EUR) | Dis 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 907.40M | -23.75% |
Gastos sa pagpapatakbo | 907.20M | 15.13% |
Net na kita | -305.00M | -217.53% |
Net profit margin | -33.61 | -254.10% |
Kita sa bawat share | -0.33 | -130.56% |
EBITDA | -266.95M | -195.92% |
Aktuwal na % ng binabayarang buwis | -34.12% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (EUR) | Dis 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 13.74B | -13.28% |
Kabuuang asset | 21.99B | -2.40% |
Kabuuang sagutin | 2.76B | -11.36% |
Kabuuang equity | 19.22B | — |
Natitirang share | 239.97M | — |
Presyo para makapag-book | 0.99 | — |
Return on assets | -3.49% | — |
Return on capital | -3.96% | — |
Cash Flow
Net change in cash
| (EUR) | Dis 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -305.00M | -217.53% |
Cash mula sa mga operasyon | 309.50M | 166.80% |
Cash mula sa pag-invest | -2.73B | -549.25% |
Cash mula sa financing | -14.30M | -95.89% |
Net change in cash | -2.42B | -1,860.74% |
Malayang cash flow | -1.44B | -27.63% |
Tungkol
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
CEO
Itinatag
2008
Website
Mga Empleyado
7,807
